Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 18, 2010Journal of Biological ChemistryOpen Access

KRASG12V Enhances Proliferation and Initiates Myelomonocytic Differentiation in Human Stem/Progenitor Cells via Intrinsic and Extrinsic Pathways

View Full Paper
Ask AI
Bookmark
Share

Key result

KRAS(G12V) transduction in human CD34+ cells induced a transient proliferative advantage and myelomonocytic differentiation mediated via ERK, p38 MAPK pathways, and secreted factors like ANGPTL6.

Population

Human cord blood (CB) CD34(+) stem/progenitor cells cultured on bone marrow stroma

Comparison

KRAS(G12V) transduction vs Control cells

Design

Preclinical

Follow-up

3 weeks

Authors

SFSzabolcs FátraiDGDjoke van GosligaLHLina Han

Discussion

Loading...

Member takes

Overview

Offers a human progenitor model for KRAS-driven myelomonocytic expansion; leaves open validation in patient samples and therapeutic targeting of ANGPTL6 or MAPK pathways.

Structured PICO

P
Population
In vitro study evaluating the effects of KRAS(G12V) transduction on human cord blood CD34(+) stem/progenitor cells.
I
Intervention
KRAS(G12V) transduction
C
Comparator
Control cells
O
Outcome
Proliferation and myelomonocytic differentiationsurrogate

KRAS(G12V) drives transient proliferation and terminal myelomonocytic differentiation in human CD34+ cells via distinct MAPK pathways and secreted factors like ANGPTL6.

Cite This Study

Fátrai et al. (2010) studied hematopoietic malignancies. KRAS(G12V) transduction vs. control cells was evaluated on proliferation and myelomonocytic differentiation. KRAS(G12V) transduction in human CD34+ cells induced a transient proliferative advantage and myelomonocytic differentiation mediated via ERK, p38 MAPK pathways, and secreted factors like ANGPTL6.

synapsesocial.com/papers/6ab08ee17e979cb029ebf481https://doi.org/10.1074/jbc.m110.201848
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1KRAS G12D Blocks Erythroid Differentiation and Promotes Inflammatory Pathways at the Single Cell Level in Myeloid Malignancies 22515712026
  2. 2Monoallelic KRAS (G13C) mutation triggers dysregulated expansion in induced pluripotent stem cell-derived hematopoietic progenitor cells2024
  3. 3Modeling KRAS mutations in KMT2A::MLLT3 acute myeloid leukemia promotes leukemic progression and transcriptional rewiring2026
  4. 4411 Molecular dynamics driving phenotypic divergence among KRAS mutants in pancreatic tumorigenesis2026
  5. 5KRAS G12C and KRAS G12D respond to lipid metabolism in an allele-specific manner2026